Immunicum enrolls the first patient in its COMBIG clinical phase I/II-trial in renal cell carcinoma.
2012-03-12 09:26 In total, 12 patients with metastasis cancer of the kidney are being treated in order to investigate possible side effects and the antitumour effect of the vaccine. "“We are looking forward to the study and hope that a future kidney cancer vaccine will help a large number of people that cannot be effectively helped today," says Jamal El-Mosleh, Immunicum´s CEO.









